NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Interventional Procedures Advisory Committee (IPAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday, 12 January 2023

**Location:** Via Zoom

# Committee members present

1. Professor Tom Clutton-Brock [Chair] Present for all items
2. Professor Colin Howie [Vice Chair] Present for all items
3. Dr Charlotta Karner Present for all items
4. Professor Dhiraj Tripathi Present for items 3, 4 (part 1), 8, 9, 10, and 11
5. Mr James Tysome Present for all items
6. Dr Jon Bell Present for all items
7. Dr Jurjees Hasan Present for items 3, 4, 5, 6, and 7
8. Ms Maria Parsonage Present for items 3, 8, 9, 10, and 11
9. Mr Marwan Habiba Present for all items
10. Professor Matt Bown Present for all items
11. Mr Matthew Metcalfe Present for items 3, 4 (part 1), 8, 9, 10, and 11
12. Mr Patrick Farrell Present for all items
13. Mrs Sally Brearley Present for all items except item 10 (part 2), and item 11
14. Dr Stuart Smith Present for all items
15. Professor Tim Kinnaird Present for all items

# Committee Apologies

1. Ms Dawn Lee
2. Dr Greg Irving
3. Miss Karen Nugent
4. Mr Mahmoud Elfar
5. Mr Mustafa Zakkar
6. Dr Paula Whittaker
7. Ms Veena Soni

# NICE staff present:

Dr Alan Ashworth – Consultant Clinical Advisor, IPP

Anastasia Chalkidou – Associate Director, IPP

Benjamin Pearce – Senior Medical Editor, Publishing

Charlie Campion – Project Manager, IPP

Chris Chesters – Technical Adviser, MTEP

Deonee Stanislaus – Coordinator, IPP

Gavin Tucker – Clinical Fellow, Quality and Leadership

Helen Gallo – Senior Health Technology Assessment Analyst, IPP

Jen Hacking – Medical Editor, Publishing

Professor John Powell – Consultant Clinical Advisor, IPP

Professor Kevin Harris – Programme Director & Consultant Clinical Advisor, IPP

Korin Knight – Senior Medical Editor, Publishing

Lakshmi Mandava – Health Technology Assessment Analyst, IPP

Lyn Davies – Coordinator, Corporate Office

Lynn Woodward – Project manager, Corporate Office

Sammy Shaw – Associate Health Technology Assessment Analyst, IPP

Xia Li – Health Technology Assessment Analyst, IPP

Ziqi Zhou – Associate Health Technology Assessment Analyst, IPP

Zoe Jones – Administrator, IPP

# 

# External group representatives present:

Valeska Seguel Ravest, Medtronic Present for item 4

Florence Brüll, Medtronic Present for item 4

Eric Grovender, Medtronic Present for items 8 and 9

Theresa Marshall, Medtronic Present for items 8 and 9

Robert Wright, Onco V Present for items 8 and 9

Barry Richards, Plasma Surgical Present for item 10

Simon Butler-Manuel, Plasma Surgical Present for item 10

Claire Jossan, EDAP-TMS Present for item 11

Christopher Arbault, EDAP-TMS Present for item 11

Karen Cornett, Sonablate Present for item 11

# Clinical & patient experts present:

Dr Sheila Lane, Consultant Paediatric Oncologist and Programme Lead for Future Fertility Programme Oxford, Oxford University Hospitals NHS Foundation Trust Present for item 3

Dr Yulia Kopeicka, Consultant Gynaecologist, Subspecialist in Reproductive Medicine, Assisted Conception Unit, Guys and St Thomas NHS Trust Present for item 3

Adel Helmy, Associate Professor, Honorary Consultant Neurosurgeon, University of Cambridge & Cambridge University Hospitals NHS Trust Present for item 4

Pragnesh Bhatt, Consultant Neurosurgeon, Aberdeen Royal Infirmary Present for item 4

1. Introduction to the meeting
   1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
   1. The chair reminded the committee to return their expression of interest forms for the vice-chair position to the IP team by 20th January 2023.
   2. The chair confirmed that the IPAC terms of reference have been updated. The chair highlighted that the quoracy level has been changed and will now be 50% of the current membership. For today’s meeting quoracy will be set at 11. The chair also highlighted that the cap on the total amount of time on the committee has been applied to the chair and vice chair roles and no longer resets. This is to align with the NICE advisory bodies policy. The chair will discuss this change with the Chief Executive and other NICE committee chairs.
   3. The chair informed the committee that the meeting in March will be a hybrid meeting and encouraged them to attend in person. Further information will be sent to the committee shortly.
3. NNP of IP1936 Removal, preservation and re-implantation of ovarian tissue to restore fertility after gonadotoxic treatment
   1. Part 1 – Open session
      1. The Chair welcomed the invited clinical experts, and members of the public.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Colin Howie declared a non-financial indirect interest as his brother worked at the MRC unit for reproductive biology which conducted research in this area before retiring 1 year ago.
* It was agreed that his declaration was not a conflict of interest and would not prevent Colin Howie from participating in this section of the meeting.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Colin Howie, who gave a presentation on the safety and efficacy of Removal, preservation and re-implantation of ovarian tissue to restore fertility after gonadotoxic treatment.
  1. Part 2 – Closed session

Clinical experts and members of the public were asked to leave the meeting: 10:17.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. NNP of IP1887 Middle Meningeal Embolisation for Chronic Subdural Haematomas (CSDH)
   1. Part 1 – Open session
      1. The Chair welcomed the invited clinical experts, members of the public and company representatives from Medtronic.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Stuart Smith declared an indirect non-financial interest as this procedure is performed at his unit, but he does not perform the procedure himself. He has also seen the procedure performed in America.
* It was agreed that his declaration was not a conflict of interest and would not prevent Stuart Smith from participating in this section of the meeting.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Dhiraj Tripathi, who gave a presentation on the safety and efficacy of Middle Meningeal Embolisation for Chronic Subdural Haematomas (CSDH).
  1. Part 2 – Closed session

Company representatives, clinical experts and members of the public were asked to leave the meeting: 11:42.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. Briefs of IP228/4 Selective internal radiation therapy for unresectable colorectal metastases in the liver
   1. Part 1 – Closed session
      1. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Jurjees Hasan declared a direct financial interest as he performs the procedure in the private sector.
* It was agreed that his declaration would not prevent Jurjees Hasan from participating in this section of the meeting.
* Jon Bell declared a direct financial interest as he is a senior medical adviser for Boston Scientific and Sirtex. He also performs this procedure in the private sector.
* It was agreed that his declaration would not prevent Jon Bell from participating in this section of the meeting.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Jon Bell, who gave a presentation on the safety and efficacy of Selective internal radiation therapy for unresectable colorectal metastases in the liver.
    2. The committee approved the content of the scope as adequate for evaluation of this procedure.

1. Briefs of IP1893 Preventive lymphovenous anastomosis (LYMPHA)
   1. Part 1 – Closed session
      1. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the procedure.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Matt Bown, who gave a presentation on the safety and efficacy of Preventive lymphovenous anastomosis (LYMPHA).
    2. The committee approved the content of the scope as adequate for evaluation of this procedure.

1. Briefs of IP1973 Intravascular lithotripsy for calcified arteries in peripheral vascular disease
   1. Part 1 – Closed session
      1. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Matt Bown declared a direct financial interest as he is the chief investigator for a company funded study.
* It was agreed that his declaration would not prevent Matt Bown from participating in this section of the meeting.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Jon Bell, who gave a presentation on the safety and efficacy of Intravascular lithotripsy for calcified arteries in peripheral vascular disease.
    2. The committee approved the content of the scope as adequate for evaluation of this procedure.

1. Public Consultation comments of IP1783 Radiofrequency ablation for palliation of painful spinal metastases
   1. Part 1 – Open session
      1. The Chair welcomed the invited members of the public and company representatives from Medtronic and Onco V.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the procedure.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then summarised the comments received during the consultation on the draft guidance for Radiofrequency ablation for palliation of painful spinal metastases.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives and members of the public were asked to leave the meeting: 13:24.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.  
         
       A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Public Consultation comments of IP1953 Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases
   1. Part 1 – Open session
      1. The Chair welcomed the invited members of the public and company representatives from Medtronic and Onco V.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the procedure.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Stuart Smith, who summarised the comments received during the consultation on the draft guidance for Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives and members of the public were asked to leave the meeting: 13:32.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.  
         
       A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Public Consultation comments of IP964/2 Maximal effort cytoreductive surgery for advanced ovarian cancer
   1. Part 1 – Open session
      1. The Chair welcomed the invited members of the public and company representatives from Plasma Surgical.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the procedure.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Tim Kinnaird, who summarised the comments received during the consultation on the draft guidance for Maximal effort cytoreductive surgery for advanced ovarian cancer.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives and members of the public were asked to leave the meeting: 13:59.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.  
         
       A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Public Consultation comments of IP839/2 Focal therapy using high-intensity focused ultrasound for localised prostate cancer
   1. Part 1 – Open session
      1. The Chair welcomed the invited members of the public and company representatives from EDAP-TMS and Sonablate.
      2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the procedure.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Patrick Farrell, who summarised the comments received during the consultation on the draft guidance for Focal therapy using high-intensity focused ultrasound for localised prostate cancer.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives and members of the public were asked to leave the meeting: 14:39.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.  
         
       A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Date of the next meeting

The next meeting of the Interventional Procedures Advisory Committee (IPAC) will be held on 09/02/2023 and will start promptly at 9am.